Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review
Fergenbaum J
Record ID 32015000712
English
Authors' recommendations:
Based on the evidence, the following conclusions can be made:
There are major harms (unnecessary risks) associated with PSA screening, including:
• harms associated with prostate biopsy
• overdiagnosis
There are minor harms associated with PSA screening including:
• harms associated with PSA testing
PSA-based screening for prostate cancer results in harms related to the screening process, biopsy procedures, and, most significantly, the treatment of overdiagnosed cases. PSA-based screening of prostate cancer results in overdiagnosis and overtreatment without providing a mortality advantage, thereby exposing men to invasive treatments and potential complications. Consequently, PSA-based screening in prostate cancer results in more harm than benefit
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hqontario.ca/Portals/0/Documents/eds/rapid-reviews/psa-screening-1505-en.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Male
- Prostatic Neoplasms
- Early Detection of Cancer
- Prostate-Specific Antigen
- Mass Screening
Contact
Organisation Name:
Health Quality Ontario
Contact Address:
Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5
Contact Name:
EDSinfo@hqontario.ca
Contact Email:
OH-HQO_hta-reg@ontariohealth.ca
Copyright:
Health Quality Ontario (HQO)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.